- Home
- PRQR vs ALDX Comparison
PRQR vs ALDX Comparison
Compare PRQR & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRQR
- ALDX
- Stock Information
- Founded
- PRQR 2012
- ALDX 2004
- Country
- PRQR Netherlands
- ALDX United States
- Employees
- PRQR N/A
- ALDX N/A
- Industry
- PRQR Biotechnology: Pharmaceutical Preparations
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- PRQR Health Care
- ALDX Health Care
- Exchange
- PRQR Nasdaq
- ALDX Nasdaq
- Market Cap
- PRQR 179.1M
- ALDX 160.8M
- IPO Year
- PRQR 2014
- ALDX 2014
- Fundamental
- Price
- PRQR $2.35
- ALDX $4.76
- Analyst Decision
- PRQR Strong Buy
- ALDX Strong Buy
- Analyst Count
- PRQR 8
- ALDX 2
- Target Price
- PRQR $8.88
- ALDX $9.50
- AVG Volume (30 Days)
- PRQR 357.1K
- ALDX 1.2M
- Earning Date
- PRQR 08-07-2025
- ALDX 07-31-2025
- Dividend Yield
- PRQR N/A
- ALDX N/A
- EPS Growth
- PRQR N/A
- ALDX N/A
- EPS
- PRQR N/A
- ALDX N/A
- Revenue
- PRQR $21,212,711.00
- ALDX N/A
- Revenue This Year
- PRQR N/A
- ALDX N/A
- Revenue Next Year
- PRQR N/A
- ALDX N/A
- P/E Ratio
- PRQR N/A
- ALDX N/A
- Revenue Growth
- PRQR 85.91
- ALDX N/A
- 52 Week Low
- PRQR $1.07
- ALDX $1.14
- 52 Week High
- PRQR $4.62
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- PRQR 66.90
- ALDX 78.74
- Support Level
- PRQR $2.10
- ALDX $4.12
- Resistance Level
- PRQR $2.18
- ALDX $4.60
- Average True Range (ATR)
- PRQR 0.13
- ALDX 0.29
- MACD
- PRQR 0.01
- ALDX 0.08
- Stochastic Oscillator
- PRQR 56.92
- ALDX 90.91
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.